A 47-year-old man developed chronic alcoholic liver cirrhosis and end-stage renal disease. He underwent blood-type-compatible liver transplantation with a graft from his daughter. After 8 months, sequential ABO-incompatible (ABOi) kidney transplantation was performed, with his brother as the donor (A to O). The patient had anti-A antibody titers (1:256). We performed pretransplant desensitization, including administration of rituximab, mycophenolate mofetil, tacrolimus, and prednisolone 2 weeks before the scheduled transplantation, and plasmaphresis (PP) and administered an intravenous immunoglobulin injection. The patient underwent PP before kidney transplantation until the anti-A antibody titer was <1:8. The patient achieved normal renal function within 4 posttransplantation days. Postoperative bleeding (diffuse hemorrhage) requiring additional blood transfusions and radiological intervention (drainage procedure) occurred 9 days after transplantation. The patient was discharged on day 20 of hospitalization. Nine months after the kidney transplantation, the recipient's and donor's liver and kidney functions were normal.
INTRODUCTION
Combined liver and kidney transplantation (CLKT) is an effective therapy for end-stage liver disease with chronic renal failure. However, it is a complex surgical procedure and difficult to manage perioperatively. Therefore, we per- In the present case, several clinical obstacles were encountered, such as liver and kidney transplantation (LKT), ABO incompatibility, and bleeding complication after multiple plasmapheresis (PP). Herein, we discuss these issues in detail.
CASE REPORT
A 47-year-old man had chronic alcoholic liver cirrhosis and unknown origin ESRD. His blood type was O Rh+. We performed blood type-compatible liver transplantation with a graft from his daughter. His Child-Turcotte-Pugh score was 5, model for end-stage liver disease score was 20, and graft-to-recipient weight ratio was 1.04. He had undergone living donor liver transplantation (LDLT) using by a modified right lobe graft and bile duct anastomosis was made by duct-to-duct. Immunosuppression consisted of prednisolone, tacrolimus, mycophenolate mofetil (500 mg/day).
The target whole-blood trough level of tacrolimus was 8∼ 10 ng/mL for the first 4 week and 7∼9 ng/mL thereafter. (Fig.   1 ). There was perinephric hematoma in the radiologic study (Fig. 2) . At postoperative day 9, we performed percutaneous drainage of the perinephric hematoma (Fig. 3) . The patient was discharged with good graft function on postoperative day 20. Three year after the procedure, the liver and renal allograft function was normal. The risk of hemorrhage after PP is increased. After PP, postoperative bleeding is not uncommon. Plasma exchange itself produces a decrease in clotting factors. However, an increase in these factors is noted in a few hours. When multiple PP sessions are performed in a short period, coagulopathy is prolonged (9) . ABOi KT usually needs several PP sessions, as in our case.
In conclusion, CLKT is an effective therapy for end-stage liver disease with chronic renal failure. However, it is a complex surgical procedure and perioperative management is difficult. Therefore, we performed SeqLKT. ABO-incompatible renal transplantation after liver transplantation can be performed successfully in patient after preconditioning with rituximab and PP, and quadruple immunosuppressive therapy. However, the intensified desensitization in patients might be associated with an increased risk of bleeding complications.
